3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
4
Pain, Postoperative
2
Vesico-Ureteral Reflux
1
Uterine Neoplasms
1
Ureteral Neoplasms
1
Peritoneal Cancer
1
Pancreatic Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Neuralgia
1
Nephrolithiasis
1
Neoplasms
1
Malignant Neoplasms of Female Genital Organs
1
Lung Neoplasms
1
Leiomyoma
1
Kidney Neoplasms
1
Endometrial Neoplasms
1
Endometrial Hyperplasia
1
Digestive System Diseases
1
Breast Cancer Female
1
Abdominal Cancer
1
Interventions
Interferon-alpha
7
aldesleukin
6
Sunitinib
6
Radiotherapy
5
Nivolumab
5
Doxorubicin
5
Vincristine
4
Ipilimumab
4
Filgrastim
4
Dactinomycin
4
Chemotherapy, Adjuvant
4
Axitinib
4
cabozantinib
3
Sorafenib
3
Everolimus
3
Etoposide
3
Cyclophosphamide
3
temsirolimus
2
pembrolizumab
2
Ifosfamide
2
G250 monoclonal antibody
2
Fluorouracil
2
Carboplatin
2
Bevacizumab
2
vitespin
1
shark cartilage extract
1
pazopanib
1
lenvatinib
1
glutamic acid diethyl ester
1
cemiplimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Kidney Neoplasms
×
Bupivacaine
×
Clear all
NCT06349668
2026-02-05
SMILe
University Hospital, Linkoeping
Phase 3
Recruiting
220 enrolled